We would like to hear about your experience using N3C Data Enclave tools! Please complete this short survey. Your feedback is very valuable to us and greatly appreciated, as it will help us to continually improve your experience in the platform, from the tooling and features to support and training materials.

We Need Just 2 Minutes of Your Time!

As part of the N3C program evaluation, we are collecting information about your experience with N3C, as well as your utilization of N3C resources. Your feedback is extremely valuable to understand what is working well and what can be improved. The brief survey should take only 1–2 minutes to complete.

       New Slack: https://bit.ly/join-n3c-pasc-slack

The viral variant summary data consists of high-level clinical information that includes at minimum the following values:

The initial viral variant data set includes data from six sites. The data set will eventually include 15 sites (eight CTSA sites and seven CTR sites).

Viral variant summary data is considered level 3 data, as are all data sets that incorporate the privacy-preserving record linkage (PPRL) or other patient linkages. The Data Use Request (DUR) has been modified to include a set of checkboxes for all currently available PPRL datasets (see image below). In addition to all standard level 3 requirements (described below), users need to choose the datasets they would like and describe their use in the DUR rational paragraph for the Data Access Committee (DAC).

This level of access requires all investigators to submit a DUR, which in turn needs a signed institutional data use agreement (DUA), a letter of determination and attestation to the N3C Code of Conduct, IT security training, and human subject training. A new checkbox has been added to the DUR form (see image below) where investigators can request access to linked data sets like mortality and viral variant prior to submission to the NCATS’ federally staffed Data Access Committee (DAC) for review.

If you have questions about accessing the viral variant summary data, please submit an N3C Support Desk ticket.

Published works using N3C data are listed on the N3C Cohort Exploration Dashboard. The Publications tab displays titles and links to fully published articles, articles online ahead of print, and published preprints, as well as a list of accepted conference presentations and posters.

“Racial disparities in COVID-19 test positivity among people living with HIV in the United States” in International Journal of STD & AIDS. (March 19, 2022)

“Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative” in Journal of Clinical Oncology. (March 14, 2022)

“Social Determinants of Health Factors for Gene–Environment COVID-19 Research: Challenges and Opportunities” in Advanced Genetics. (March 9, 2022)

“Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19” in JAMA Network Open. (March 1, 2022)

“Ankle Fracture and Length of Stay in US Adult Population Using Data From the National COVID Cohort Collaborative” in Foot & Ankle Orthopaedics. (Feb. 24, 2022)

“Breakthrough SARS-CoV-2 Infection Outcomes in Vaccinated Patients with Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study” on medRxiv. (Feb. 26, 2022)

When you have a research product that is ready for publication or accepted for presentation, please submit it via the N3C Publication Intent Form, which will notify the Publication Committee of N3C output to be registered. (Research products include: manuscripts, posters, conference papers, blogs, press releases, podium presentations, etc.)

Per the N3C Attribution and Publication Principles, all manuscripts using N3C community resources must be reviewed by the Publication Committee. Non-manuscript products do not require review but should be submitted after they have been accepted by the conference to allow for promotion and tracking of collaborator accomplishments.

View the Publication Review web page for more details.

N3C recently launched the Public Health Browser, which provides snapshots of high-value health data for policy makers, investigators, and entrepreneurs to facilitate further research questions for better health outcomes. 

With the launch of the Public Health Browser, aggregate summary data is now available for stakeholders to access sample sizes of relevant data cohorts without requesting access to the N3C Data Enclave, which can only be accessed through a secure cloud portal.

There will be two to three dashboards added in the near future that will include snapshots of long COVID/post-acute sequelae of SARS-CoV-2 (PASC), mortality, and possibly a reinfection time series. N3C will continue to add new dashboards to the Public Health Browser as new data sets become available.

Explore N3C’s Public Health Browser to learn more, or email cd2h@ohsu.edu with questions or comments.

Thank you to everyone who represented N3C at the American Medical Informatics Association (AMIA) 2022 Informatics Summit in Chicago last week! It was great to see many of the CD2H and N3C team members in person — some for the first time, others for the first time in more than two years!

Speakers: Adam Wilcox, Boyd Knosp, Jodyn Platt, Nicholas Anderson, Genevieve Melton-Meaux, William Barnett, Justin Starren

Speakers: Christopher Chute, Anita Walden, Emily Pfaff, Davera Gabriel, Charisse Madlock-Brown

Speakers: Laura Wiley (session chair), Jennifer Pacheco, Elise Lang, Lily Cook, Jimmy Phuong, Hanieh Razzaghi, Alexandra Rizaldi

Speaker: Lily Cook

Speakers: Jimmy Phuong, Stephanie Hong

Speakers: Adam Wilcox, Anita Walden, Christopher Chute, Randi Foraker, Alexis Graves

Speakers: Anthony Solomonides, Dina Paltoo, Charisse Madlock-Brown, Jimmy Phuong, Arash Shaban-Nejad, Vignesh Subbian, Naoko Muramatsu

Speakers: Umberto Tachinardi, Abel Kho, Kenneth Gersing, Jasmin Phua

Speaker: Olga Kravchenko

Healio: Early aspirin use may lower mortality risk in adults hospitalized with COVID-19 (March 24, 2022)

Among patients hospitalized with moderate COVID-19, those who received aspirin on the first day of hospitalization had a significantly lower risk for 28-day mortality than those who did not, according to a recent observational cohort study.

Endocrinology Advisor: Glycemic Control a Risk Factor for Poor COVID-19 Outcomes Among Patients With Type 2 Diabetes (March 21, 2022)

Poor glycemic control was found to be associated with increased risk for COVID-19 hospitalization and mortality, according to the results of a retrospective study published in Diabetes Care.

MedPage Today: It's Not Over for Aspirin in Moderate COVID-19 (March 24, 2022)

People with moderate COVID-19 illness tended to have better clinical outcomes if they took aspirin their first day in the hospital, according to data from the NIH's National COVID Cohort Collaborative.

New Canaan Advertiser: CT researchers validate long COVID as disabling: It’s not ‘all in your head' (March 9, 2022)

Sen. Tim Kaine, D-Va., introduced the CARE for Long COVID Act. The bill seeks to encourage more research and provide resources for those suffering from lingering COVID-19 symptoms and other post-viral illnesses. In a press release, Kaine acknowledged that he is enduring mild long COVID symptoms himself.

POZ: COVID Vaccine Boosters Protect People With Immune Dysfunction (March 9, 2022)

Receiving an additional COVID-19 vaccine dose provided more protection for people with compromised immunity, according to research presented at the Conference on Retroviruses and Opportunistic Infections 2022 (CROI 2022). While the study did not analyze booster effectiveness based on the specific type of immune dysfunction, it does offer reassurance that this population can benefit from keeping up to date on vaccination.

News Medical: Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients (March 3, 2022)

The development of safe and effective vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly altered the course of the coronavirus disease 2019 (COVID-19) pandemic. Both clinical trials and real-world evidence have demonstrated that current COVID-19 vaccines are extremely effective, particularly in reducing the risk of severe disease.

Contemporary Pediatrics: What factors are linked to severe COVID-19 in children? (February 23, 2022)

Since the start of the COVID-19 pandemic, the general understanding of how the disease affects children has shifted, from being seen as a disease with little to no impact on children to children being a significant proportion of patients contracting the virus. However, a lack of large cohort studies has made it difficult to build a robust knowledge base. A recent report sheds some much needed light.

In the event that you come across activities that pose misalignment with the principles outlined in the Community Guiding Principles for the National COVID Cohort Collaborative (N3C), you can privately notify us using the Report Conduct Concerns form located on the N3C website under the SUPPORT menu. Your feedback is important and we will take prompt and confidential action to address your concerns. All data management incidents should also be reported to NCATS. Thank you for your contribution!

The National COVID Cohort Collaborative (N3C) is a complementary and synergistic partnership among the Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), distributed clinical data networks (PCORnet, OHDSI, ACT, TriNetX), and other partner organizations, with overall stewardship by NIH’s National Center for Advancing Translational Sciences (NCATS). The N3C aims to improve the efficiency and accessibility of analyses using a very large row-level (patient-level) COVID-19 clinical dataset, demonstrate a novel approach for collaborative pandemic data sharing, and speed understanding of and treatments for COVID-19.